Active targeting

Fundamentals of Pharmaceutical Nanoscience

Volumn , Issue , 2013, Pages 337-374

  Serrano Lopez, Dolores Remedios ^a   Lalatsa, Aikaterini ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUNCTIONAL POLYMERS; LIPOSOMES; MEDICAL NANOTECHNOLOGY; OLIGONUCLEOTIDES; PROTEINS;

ACTIVE TARGETING; CANCER AND CENTRAL NERVOUS SYSTEMS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; IMAGING AGENT; NANOCARRIERS; PROOF OF CONCEPT;

TARGETED DRUG DELIVERY;

EID: 84930506700     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9164-4_13     Document Type: Chapter

References (182)

1. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM (2001) High affinity restricts the localization and tumour penetration of single-chain fv antibody molecules. Cancer Res 61(12):4750–4755
2. Aktas Y, Yemisci M, Andrieux K, Gursoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Riguera R, Sargon MF, Celik HH, Demir AS, Hincal AA, Dalkara T, Capan Y, Couvreur P (2005) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 16(6):1503–1511
3. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505–515
4. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10): 750–763
5. Allen D, Smith Q (2001) Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique. J Neurochem 76(4):1032–1041
6. Allen T, Hansen C, Stuart D (1998) Targeted sterically stabilized liposomal drug delivery: an overview. In: Lasic D, Papahadjopoulos D (eds) Medical applications of liposomes. Elsevier, Amsterdam, pp 297–323
7. Bader R (2012) The development of targeted drug delivery systems for rheumatoid arthritis treatment. In: Lemmey A (ed) Rheumatoid arthritis—treatment. Available from: http://www.intechopen.com/books/rheumatoid-arthritis-treatment/the-development-of-targeteddrug-delivery-systemsfor-rheumatoid-arthritis-treatment, In Tech., pp 111–132
8. Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153(3):198–205
9. Baker C, Fidler I (2007) Antiangiogenic cancer therapy. CRC Press, Boca Raton Ballet F (1990) Hepatic circulation: potential for therapeutic intervention. Pharmacol Ther 47(2):281–328
10. Barrett GL, Trieu J, Naim T (2009) The identification of leptin-derived peptides that are taken up by the brain. Regul Pept 155(1–3):55–61
11. Baselga J (2001) Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61(suppl 2):14–21
12. Beduneau A, Saulnier P, Benoit JP (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28(33):4947–4967
13. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104(1):29–45
14. Berg J, Tymoczko J, Stryer L (2002) Section 11.4: Lectins are specific carbohydrate-binding proteins. In: Biochemistry, 5th edition, W. H. Freeman and Company, New York
15. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P, European NanoBioPharmaceutics Research Initiative (2009) Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 87(4):212–251
16. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615–1626
17. Cai LL, Liu P, Li X, Huang X, Ye YQ, Chen FY, Yuan H, Hu FQ, Du YZ (2011) RGD peptidemediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomedicine 6:3499–3508
18. Calando Pharmaceuticals Inc. (2013) Safety study of CALAA-01 to treat solid tumor cancers. http://www.clinicaltrials.gov/ct2/show/NCT00689065. Accessed 14 March 2013
19. Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, Cole DJ, Chang EH, Watson DK (2013) Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 20(4):222–228
20. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(suppl 3):4–10
21. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1(2):118–129
22. Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54(4):531–545
23. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17(8):780–783
24. Chen Q, Massague J (2012) Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin Cancer Res 18(20):5520–5525
25. Chen J, Wu H, Han D, Xie C (2006) Using anti-VEGF McAb and magnetic nanoparticles as doubletargeting vector for the radioimmunotherapy of liver cancer. Cancer Lett 231(2):169–175
26. Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY (2010) Self- assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31(1):106–114
27. Choi KY, Yoon HY, Kim JH, Bae SM, Park RW, Kang YM, Kim IS, Kwon IC, Choi K, Jeong SY, Kim K, Park JH (2011) Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 5(11):8591–8599
28. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P (1996) Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 13(3):245–255
29. Clark D, Mao L (2012) Cancer biomarker discovery: lectin-based strategies targeting glycoproteins. Dis Markers 33(1):1–10
30. Csaba N, Garcia-Fuentes M, Alonso MJ (2006) The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Deliv 3(4):463–478
31. Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135–146
32. Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820(3):291–317
33. Das A, Soehnlen E, Woods S, Hegde R, Henry A, Gericke A, Basu S (2011) VEGFR-2 targeted cellular delivery of doxorubicin by gold nanoparticles for potential antiangiogenic therapy. J Nanopart Res 13:6283–6290
34. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6(3):659–668
35. Decuzzi P, Causa F, Ferrari M, Netti PA (2006) The effective dispersion of nanovectors within the tumor microvasculature. Ann Biomed Eng 34(4):633–641
36. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, Gabathuler R, Castaigne JP, Beliveau R (2008) Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 106(4):1534–1544
37. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22
38. Di L, Artursson P, Avdeef A, Ecker GF, Faller B, Fischer H, Houston JB, Kansy M, Kerns EH, Kramer SD, Lennernas H, Sugano K (2012) Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov Today 17(15–16):905–912
39. Dillman RO (2001) Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 19(8):833–841
40. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J (2003) Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278(33):31192–31201
41. Dufes C, Uchegbu IF, Schatzlein AG (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev 57(15):2177–2202
42. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):688–701
43. EMEA (2006) Scientific discussion on Pegaptanib. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000620/WC500026218.pdf. Great Britain, pp 1–39. Accessed 15 Feb 2013
44. Eulberg D, Klussmann S (2003) Spiegelmers: biostable aptamers. Chembiochem 4(10):979–983
45. Fang X, Tan W (2010) Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 43(1):48–57
46. Folkman J (1996) Fighting cancer by attacking its blood supply. Sci Am 275(3):150–154
47. Fonseca SB, Pereira MP, Kelley SO (2009) Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61(11):953–964
48. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55(6):1189–1193
49. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 37(1):48–57
50. Gan CW, Feng SS (2010) Transferrin-conjugated nanoparticles of poly(lactide)-D-alphatocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 31(30):7748–7757
51. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE (2007) Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2(4):249–255
52. Genis L, Galvez BG, Gonzalo P, Arroyo AG (2006) MT1-MMP: universal or particular player in angiogenesis? Cancer Metastasis Rev 25(1):77–86
53. Gerber DE (2008) Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77(3):311–319
54. Goodsell DS (1999) The molecular perspective: methotrexate. Oncologist 4(4):340–341
55. Gosk S, Moos T, Gottstein C, Bendas G (2008) VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 1778(4):854–863
56. Gromnicova R, Davies H, Sreekanthreddy S, Romero I, Phillips J, Male D (2012) Poster 57: Transcytosis of glucose-coated gold nanoparticles across brain endothelium in vitro. NANOMED, University College of London, 7–9 th November 2012, London, UK.
57. Gu G, Xia H, Hu Q, Liu Z, Jiang M, Kang T, Miao D, Tu Y, Pang Z, Song Q, Yao L, Chen H, Gao X, Chen J (2013) PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 34(1):196–208
58. He Y, Zhang L, Song C (2010) Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes. Int J Nanomedicine 5:697–705
59. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95(8):4607–4612
60. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr, Banaszak Holl MM (2007) The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 14(1):107–115
61. Huang R, Ke W, Han L, Liu Y, Shao K, Jiang C, Pei Y (2010) Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull 81(6):600–604
62. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J (2002) By-passing of P-glycoprotein using immunoliposomes. J Drug Target 10(1):73–79
63. Jain KK (2008) Drug delivery systems—an overview. Methods Mol Biol 437:1–50
64. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101(51): 17867–17872
65. Jones MC, Gao H, Leroux JC (2008) Reverse polymeric micelles for pharmaceutical applications. J Control Release 132(3):208–215
66. Kakar SS, Jin H, Hong B, Eaton JW, Kang KA (2008) LHRH receptor targeted therapy for breast cancer. Adv Exp Med Biol 614:285–296
67. Kang YS, Terasaki T, Ohnishi T, Tsuji A (1990) In vivo and in vitro evidence for a common carrier mediated transport of choline and basic drugs through the blood-brain barrier. J Pharmacobiodyn 13(6):353–360
68. Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, Kaplowitz N (1990) Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 85(6):2009–2013
69. Kanwar J, Samarasinghe R, Sehgal R, Kanwar R (2012) Nano-lactoferrin in diagnostic, imaging and targeted delivery for cancer and infectious diseases. J Cancer Sci Ther 4:031–042
70. Karande AA, Sridhar L, Gopinath KS, Adiga PR (2001) Riboflavin carrier protein: a serum and tissue marker for breast carcinoma. Int J Cancer 95(5):277–281
71. Kasai T, Nakamura K, Vaidyanath A, Chen L, Sekhar S, El-Ghlban S, Okada M, Mizutani A, Kudoh T, Murakami H, Seno M (2012) Chlorotoxin fused to IgG-Fc inhibits glioblastoma cell motility via receptor-mediated endocytosis. J Drug Deliv 2012:975763
72. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J, Jiang C (2009) Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30(36):6976–6985
73. Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119(2):243–250
74. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36(1):66–75
75. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66(13): 6732–6740
76. Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N (2004) Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 108(2):301–306
77. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR Jr (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65(12):5317–5324
78. Kumar S, Li C (2001) Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol 22(3):129
79. Kuohung W, Burnett M, Mukhtyar D, Schuman E, Ni J, Crowley WF, Glicksman MA, Kaiser UB (2010) A high-throughput small-molecule ligand screen targeted to agonists and antagonists of the G-protein-coupled receptor GPR54. J Biomol Screen 15(5):508–517
80. Kwon GS (2003) Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20(5):357–403
81. Lalatsa A, Schätchlein AG, Uchegbu IF (2012a) Chapter 7.1: nanostructures overcoming the blood-brain barrier: physiological considerations and mechanistic issues. In: Alonso MJ, Csaba N (eds) Nanostructured biomaterials for overcoming biological barriers. Royal Society of Chemistry, London, pp 329–363. doi: 10.1039/9781849735292-00329
82. Lalatsa A, Schatzlein AG, Mazza M, Le TB, Uchegbu IF (2012b) Amphiphilic poly(L-amino acids)—new materials for drug delivery. J Control Release 161(2):523–536
83. Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161(2):175–187
84. Lee HJ, Pardridge WM (2001) Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug Chem 12(6):995–999
85. Lee CC, MacKay JA, Frechet JM, Szoka FC (2005) Designing dendrimers for biological applications. Nat Biotechnol 23(12):1517–1526
86. Lee JF, Stovall GM, Ellington AD (2006) Aptamer therapeutics advance. Curr Opin Chem Biol 10(3):282–289
87. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 58(4):1215–1227
88. Li N, Larson T, Nguyen HH, Sokolov KV, Ellington AD (2010) Directed evolution of gold nanoparticle delivery to cells. Chem Commun (Camb) 46(3):392–394
89. Li J, Zhou L, Ye D, Huang S, Shao K, Huang R, Han L, Liu Y, Liu S, Ye L, Lou J, Jiang C (2011) Choline-derivate-modified nanoparticles for brain-targeting gene delivery. Adv Mater 23(39):4516–4520
90. Litzinger DC, Buiting AM, van Rooijen N, Huang L (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1190(1):99–107
91. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H (2007) In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2(1):47–52
92. Liu L, Xu K, Wang H, Tan PK, Fan W, Venkatraman SS, Li L, Yang YY (2009) Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 4(7):457–463
93. Lockman PR, Allen DD (2002) The transport of choline. Drug Dev Ind Pharm 28(7):749–771
94. Lopes de Menezes DE, Pilarski LM, Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58(15):3320–3330
95. Low PS, Antony AC (2004) Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 56(8):1055–1058
96. Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41(1):120–129
97. Lu W, Sun Q, Wan J, She Z, Jiang XG (2006) Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 66(24):11878–11887
98. Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74(1–3):47–61
99. Managit C, Kawakami S, Nishikawa M, Yamashita F, Hashida M (2003) Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int J Pharm 266(1–2):77–84
100. Manosroi J, Lohcharoenkal W, Gotz F, Werner RG, Manosroi W, Manosroi A (2012) Polioviral receptor binding ligand: a novel and safe peptide drug carrier from polioviral capsid. Drug Deliv 19(1):21–27
101. Master AM, Sen Gupta A (2012) EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine (Lond) 7(12):1895–1906
102. Maynard J, Georgiou G (2000) Antibody engineering. Annu Rev Biomed Eng 2:339–376
103. McGonigle P (2012) Peptide therapeutics for CNS indications. Biochem Pharmacol 83(5):559–566
104. Mebiopharm Co. Ltd. (2013) Safety study of MBP-426 (liposomal oxaliplatin suspension for injection) to treat advanced or metastatic solid tumors. http://www.clinicaltrials.gov/ct/show/NCT00355888; pipeline in http://www.mebiopharm.com/english/pro.html. Accessed 2 March 2013
105. Meng S, Su B, Li W, Ding Y, Tang L, Zhou W, Song Y, Caicun Z (2011) Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol 28(4):1180–1187
106. Milane L, Duan Z, Amiji M (2011a) Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 6(9):e24075
107. Milane L, Duan ZF, Amiji M (2011b) Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine 7(4):435–444
108. Mills J, Needham D (1999) Targeted drug delivery. Exp Opin Ther Patents 9:1499–1513
109. Milosevic M, Fyles A, Hedley D, Hill R (2004) The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14(3):249–258
110. Minko T (2004) Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 56(4):491–509
111. Nance EA, Woodworth GF, Sailor KA, Shih TY, Xu Q, Swaminathan G, Xiang D, Eberhart C, Hanes J (2012) A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med 4(149):149ra119
112. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5(2):123–132
113. Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics. Annu Rev Med 56:555–583
114. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS (2003) Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6(2):105–119
115. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, Lobb R (1989) Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59(6):1203–1211
116. Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51(3):227–238
117. Owens DE III, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307(1):93–102
118. Paleos CM, Tsiourvas D, Sideratou Z, Tziveleka LA (2010) Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opin Drug Deliv 7(12):1387–1398
119. Paliwal SR, Paliwal R, Agrawal GP, Vyas SP (2011) Liposomal nanomedicine for breast cancer therapy. Nanomedicine (Lond) 6(6):1085–1100
120. Pardridge W (1995) Transport of small molecules through the blood–brain barrier: biology and methodology. Adv Drug Deliv Rev 15(1–3):5–36
121. Pardridge WM (2007) shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 59(2–3):141–152
122. Pardridge WM (2012) Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 32(11):1959–1972
123. Pardridge WM, Boado RJ (2012) Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 503:269–292
124. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8(4):1172–1181
125. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60(3):722–727
126. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M (2003) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63(21):7400–7409
127. Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9(8):615–627
128. Pham W, Zhao BQ, Lo EH, Medarova Z, Rosen B, Moore A (2005) Crossing the blood-brain barrier: a potential application of myristoylated polyarginine for in vivo neuroimaging. Neuroimage 28(1):287–292
129. Phillips DC, Woollard KJ, Griffiths HR (2003) The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 138(3):501–511
130. Potti A, Rusconi CP, Sullenger BA, Ortel TL (2004) Regulatable aptamers in medicine: focus on antithrombotic strategies. Expert Opin Biol Ther 4(10):1641–1647
131. Rai S, Paliwal R, Vaidya B, Khatri K, Goyal AK, Gupta PN, Vyas SP (2008) Targeted delivery of doxorubicin via estrone-appended liposomes. J Drug Target 16(6):455–463
132. Re M, Pampillo M, Savard M, Dubuc C, McArdle CA, Millar RP, Conn PM, Gobeil F Jr, Bhattacharya M, Babwah AV (2010) The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane. PLoS One 5(7):e11489
133. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11(4):575–580
134. Reddy P, Swarnalatha D (2010) Recent advances in novel drug delivery systems. Int J PharmTech Res 2(3):2025–2027
135. Rippe B, Rosengren BI, Carlsson O, Venturoli D (2002) Transendothelial transport: the vesicle controversy. J Vasc Res 39(5):375–390
136. Ross JF, Chaudhuri PK, Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73(9):2432–2443
137. Ruoslahti E (2002) Specialization of tumor vasculature. Nat Rev Cancer 2:83–90
138. Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 98(10):1625–1633
139. Salmaso S, Semenzato A, Caliceti P, Hoebeke J, Sonvico F, Dubernet C, Couvreur P (2004) Specific antitumor targetable beta-cyclodextrin-poly(ethylene glycol)-folic acid drug delivery bioconjugate. Bioconjug Chem 15(5):997–1004
140. Salvador-Morales C, Zhang L, Langer R, Farokhzad OC (2009) Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30(12):2231–2240
141. Sato H, Takino T, Miyamori H (2005) Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 96(4):212–217
142. Schmidt N, Mishra A, Lai GH, Wong GC (2010) Arginine-rich cell-penetrating peptides. FEBS Lett 584(9):1806–1813
143. Senter PD, Springer CJ (2001) Selective activation of anticancer prodrugs by monoclonal antibodyenzyme conjugates. Adv Drug Deliv Rev 53(3):247–264
144. Serrano-Lopez DR, Lalatsa A (2013) Oral peptide pill for brain diseases? Reality and future perspectives. Ther Deliv 4(4):479–501
145. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ, Cancer Research Campaign Phase I/II Clinical Trials committee (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20(6):1668–1676
146. Shen Z, Wei W, Tanaka H, Kohama K, Ma G, Dobashi T, Maki Y, Wang H, Bi J, Dai S (2011) A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. Pharmacol Res 64(4):410–419
147. Singh A, Dilnawaz F, Sahoo SK (2011) Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One 6(11):e26803
148. Stohrerm M, Boucher Y, Stangassinger M, Jain R (2000) Oncotic pressure in solid tumors is elevated. Cancer Res 60:4251–4255
149. Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K (2008) Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 346(1–2):143–150
150. Swami A, Shi A, Gadde S, Votruba A, Kolishetti N, Farokhzad O (2012) Chapter 2: nanoparticles for targeted and temporally controlled drug delivery. In: Svenson S, Prud’homme R (eds) Multifunctional nanoparticles for drug delivery applications: imaging, targeting, and delivery, nanostructure science and technology. Springer, New York, pp 9–29
151. SynerGene Therapeutics, Inc. (2013) Safety study of infusion of SGT-53 to treat solid tumors. http://clinicaltrials.gov/ct2/show/NCT00470613. Accessed 2 March 2013
152. Taheri A, Dinarvand R, Atyabi F, Ahadi F, Nouri FS, Ghahremani MH, Ostad SN, Borougeni AT, Mansoori P (2011) Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with luteinizing hormone-releasing hormone (LHRH) peptide. Int J Mol Sci 12(7):4591–4608
153. Thomas TP, Huang B, Choi SK, Silpe JE, Kotlyar A, Desai AM, Zong H, Gam J, Joice M, Baker JR Jr (2012) Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic. Mol Pharm 9(9):2669–2676
154. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4(7):528–539
155. Torchilin V (2008) Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5(9):1003–1025
156. Tosi G, Badiali L, Ruozi B, Vergoni A, Bondioli L, Ferrari A, Rivasi F, Forni F, Vandelli M (2012) Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine 7(3):365–382
157. Triguero D, Buciak JB, Yang J, Pardridge WM (1989) Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci USA 86(12):4761–4765
158. Tsuji A (2005) Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2(1):54–62
159. Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptorantibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71(2):251–256
160. Ulbrich K, Knobloch T, Kreuter J (2011) Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 19(2):125–132
161. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60(2):203–212
162. Veiseh O, Gunn JW, Zhang M (2010) Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 62(3):284–304
163. Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV (2013) Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine 9(1):111–121
164. Vihinen P, Ala-aho R, Kahari V (2010) Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5(3):203–20
165. Vorbrodt AW, Dobrogowska DH, Lossinsky AS (1996) Ultrastructural study on the interaction of native and cationized albumin-gold complexes with mouse brain microvascular endothelium. J Neurocytol 25(11):645–657
166. Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, Vogel T, Worek F, Pietrzik CU, Kreuter J, von Briesen H (2012) Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One 7(3):e32568
167. Weinberg WC, Frazier-Jessen MR, Wu WJ, Weir A, Hartsough M, Keegan P, Fuchs C (2005) Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 24(4):569–584
168. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L (2005) Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23(11):1418–1423
169. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH (2008) The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 60(4–5):452–472
170. Wu H, Chang D, Huang C (2006) Targeted therapy for cancer. J Cancer Mol 2(2):57–66
171. Xie F, Yao N, Qin Y, Zhang Q, Chen H, Yuan M, Tang J, Li X, Fan W, Zhang Q, Wu Y, Hai L, He Q (2012) Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting. Int J Nanomedicine 7:163–175
172. Xu Z, Zhou X, Shi W, Qian Q (2008) Capsid modification of adeno-associated virus and tumor targeting gene therapy. Chinese Sci Bull 53(24):3790–3797
173. Xu J, Zhao JH, Liu Y, Feng NP, Zhang YT (2012) RGD-modified poly(D, L-lactic acid) nanoparticles enhance tumor targeting of oridonin. Int J Nanomedicine 7:211–219
174. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF (2013) Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev 65(1): 121–138
175. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M (1997) Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res 57(13):2799–2805
176. Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A, Averbuch S, Wadsworth P (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23(5A):3639–3650
177. Yokoyama M (2005) Drug targeting with nano-sized carrier systems. J Artif Organs 8(2):77–84
178. Yu MK, Park J, Jon S (2012) Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2(1):3–44
179. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Buchel C, von Briesen H, Kreuter J (2009) Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 137(1):78–86
180. Zhang Y, Pardridge WM (2009) Near complete rescue of experimental Parkinson’s disease with intravenous, non-viral GDNF gene therapy. Pharm Res 26(5):1059–1063
181. Zhao P, Wang H, Yu M, Liao Z, Wang X, Zhang F, Ji W, Wu B, Han J, Zhang H, Wang H, Chang J, Niu R (2012) Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur J Pharm Biopharm 81(2):248–256
182. Zhu H, Cao J, Cui S, Qian Z, Gu Y (2013) Enhanced tumor targeting and antitumor efficacy via hydroxycamptothecin-encapsulated folate-modified N-succinyl-N′-octyl chitosan micelles. J Pharm Sci 102(4):1318–1332